Boston Scientific Corporation (NYSE:BSX) quarterly revenue fell short of expectations due to lower sales of its implantable defibrillators and pacemakers, sending its shares down as much as 6 percent. Boston Scientific Corporation (NYSE:BSX) shares after opening at $12.79 moved to $13.32 on last trade day and at the end of the day closed at $12.73. Company price to sales ratio in past twelve months was calculated as 2.36 and price to cash ratio as 77.64. Boston Scientific Corporation (NYSE:BSX) showed a negative weekly performance of -7.42%.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that theUniversity of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II clinical trial evaluating Trimesta™ (oral estriol), the Company’s oral, once-daily treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Synthetic Biologics Inc (NYSEMKT:SYN) shares fell -27.84% in last trading session and ended the day on $2.10. SYN return on equity ratio is recorded as -115.80% and its return on assets is -110.30%. Synthetic Biologics Inc (NYSEMKT:SYN) yearly performance is 37.25%.
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28, 2014 at 3:45 PM local time. ACOG is the nation’s leading group of physicians providing health care for women. Palatin Technologies, Inc. (NYSEMKT:PTN) shares moved down -5.30% in last trading session and was closed at $1.25, while trading in range of $1.20-$1.38. Palatin Technologies, Inc. (NYSEMKT:PTN) year to date performance is 71.23%.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it commenced patient screening for pharmacokinetic, or PK, and food effect studies of aramchol. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) weekly performance is -10.65%. On last trading day company shares ended up $8.14. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) distance from 50-day simple moving average is -26.27%.
Leave a Reply